Are all hypotheses generated before data analysis prospective?

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1431-1433

  Urba, Walter J ^a   Alvord, W Gregory ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EDITORIAL; HUMAN; LIVER METASTASIS; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0037087619     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.6.1431     Document Type: Editorial

References (6)

1. Prognostic factors in 1,521 melanoma patients with distant metastases
2. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
3. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M. D. Anderson Cancer Center experience
4. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukine-2 alone in patients with metastatic melanoma
5. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
6. Commentary on cytoreduction nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group trial 8949